OTC · CMXC
Cell MedX Corp.
Healthcare · Medical - Devices
$0.43
Up+$0.00 (+0.00%)
Updated Sep 13, 2026, 10:30 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 126.33M
- P/E ratio
- -11.29
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 0
- Avg. volume
- 489
Price performance
CMXC price history
1M range · 0 trading sessions · Daily adjusted prices
CMXC does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest CMXC news
The latest Smart Investors Daily articles mentioning CMXC.
Stock researchCompany · Overview
CMXC research
Overview
Company profile and research snapshot.
Company profile
Cell MedX Corp., a biotech company, focuses on the discovery, development, and commercialization of therapeutic and non-therapeutic products for patients with diabetes, Parkinson's disease, high blood pressure, neuropathy, and kidney functions. It develops and manufactures eBalance Pro System for professional use by healthcare practitioners in a clinical setting; and eBalance Home System for home use for general wellness and pain management treatment, which are controlled by the eBalance Console that acts as the central controller for three pre-programmed microcurrent algorithms, including wellness, pain management, and dual. The company was formerly known as Sports Asylum, Inc. and changed its name to Cell MedX Corp. in September 2014. Cell MedX Corp. was incorporated in 2010 and is based in Carson City, Nevada.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
